{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:28Z","timestamp":1787181868372,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017413","name":"Innovation Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119751","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:31:11Z","timestamp":1784932271000},"page":"119751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual bispecific protein engager\u2013armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma"],"prefix":"10.1016","volume":"202","author":[{"given":"Thanida","family":"Chanpong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-9948","authenticated-orcid":false,"given":"Nunghathai","family":"Sawasdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-9055","authenticated-orcid":false,"given":"Kamonlapat","family":"Supimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0612-0981","authenticated-orcid":false,"given":"Thanich","family":"Sangsuwannukul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2205-6905","authenticated-orcid":false,"given":"Thaweesak","family":"Chieochansin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-3000","authenticated-orcid":false,"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biopha.2026.119751_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119751_bib2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119751_bib3","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: Idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.biopha.2026.119751_bib4","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA approval summary: Ciltacabtagene autoleucel for relapsed or refractory multiple myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.biopha.2026.119751_bib5","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","article-title":"FDA approval summary: Teclistamab-A bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma","volume":"30","author":"Baines","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119751_bib6","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119751_bib7","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.biopha.2026.119751_bib8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: First approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2026.119751_bib9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2026.119751_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Via","year":"2021","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119751_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.biopha.2026.119751_bib12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119751_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.biopha.2026.119751_bib14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J. Immunother."},{"issue":"28","key":"10.1016\/j.biopha.2026.119751_bib15","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1073\/pnas.1000976107","article-title":"T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells","volume":"107","author":"Lutterbuese","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biopha.2026.119751_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOH.0000000000000176","article-title":"Activated T cells armed with bispecific antibodies kill tumor targets","volume":"22","author":"Bhutani","year":"2015","journal-title":"Curr. Opin. Hematol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119751_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"Pt 2","key":"10.1016\/j.biopha.2026.119751_bib18","article-title":"Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells","volume":"143","author":"Supimon","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119751_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-024-05923-z","article-title":"Engineered T cells secreting \u03b1B7-H3-\u03b1CD3 bispecific engagers for enhanced anti-tumor activity against B7-H3-positive multiple myeloma: A novel therapeutic approach","volume":"23","author":"Rujirachaivej","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119751_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117878","article-title":"Enhancing T cell cytotoxicity in multiple myeloma with bispecific \u03b1PD-L1 \u00d7 \u03b1CD3 T-cell engager-armed T cells and low-dose bortezomib therapy","volume":"184","author":"Sawasdee","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119751_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118820","article-title":"Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity","volume":"193","author":"Sontayananon","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2026.119751_bib22","first-page":"392","article-title":"Bispecific protein engager-armed T cells (BATs): Next-generation platforms for precision cancer immunotherapy","volume":"78","author":"Yenchitsomanus","year":"2026","journal-title":"Siriraj Med. J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119751_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119751_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.it.2014.10.007","article-title":"Force and affinity in ligand discrimination by the TCR","volume":"35","author":"Depoil","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biopha.2026.119751_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1434463","article-title":"Rigid crosslinking of the CD3 complex leads to superior T cell stimulation","volume":"15","author":"Nelson","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119751_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67195","article-title":"Structural variability and concerted motions of the T cell receptor-CD3 complex","volume":"10","author":"Pandey","year":"2021","journal-title":"Elife"},{"issue":"32","key":"10.1016\/j.biopha.2026.119751_bib27","doi-asserted-by":"crossref","first-page":"19796","DOI":"10.1074\/jbc.M115.663799","article-title":"Identification of the docking site for CD3 on the T cell receptor beta chain by solution NMR","volume":"290","author":"He","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119751_bib28","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.4049\/jimmunol.1000732","article-title":"Distinctive CD3 heterodimeric ectodomain topologies maximize antigen-triggered activation of alpha beta T cell receptors","volume":"185","author":"Kim","year":"2010","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119751_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119751_bib30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The landscape of T cell antigens for cancer immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2026.119751_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev-biophys-042910-155238","article-title":"Receptor signaling clusters in the immune synapse","volume":"41","author":"Dustin","year":"2012","journal-title":"Annu. Rev. Biophys."},{"issue":"5","key":"10.1016\/j.biopha.2026.119751_bib32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.immuni.2013.08.036","article-title":"A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells","volume":"39","author":"Huang","year":"2013","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.biopha.2026.119751_bib33","doi-asserted-by":"crossref","first-page":"21651","DOI":"10.1002\/cam4.6721","article-title":"The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"issue":"20","key":"10.1016\/j.biopha.2026.119751_bib34","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1073\/pnas.0402295101","article-title":"Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3","volume":"101","author":"Kjer-Nielsen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119751_bib35","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2025.08.004","article-title":"Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers","author":"Lee","year":"2025","journal-title":"Semin. Hematol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119751_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133757","article-title":"Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody","volume":"5","author":"Staflin","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.biopha.2026.119751_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/85286","article-title":"Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex","volume":"2","author":"Kalergis","year":"2001","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119751_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/cei\/uxad120","article-title":"Tuning the potency and selectivity of ImmTAC molecules by affinity modulation","volume":"215","author":"Robertson","year":"2024","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119751_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2010.02.008","article-title":"The synapse and cytolytic machinery of cytotoxic T cells","volume":"22","author":"Jenkins","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2026.119751_bib40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119751_bib41","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2026.119751_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119751_bib43","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.4049\/jimmunol.0804211","article-title":"Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells","volume":"182","author":"Grosso","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119751_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltaf015","article-title":"Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4(+) T cell activation","volume":"5","author":"Sheriff","year":"2025","journal-title":"Immunother. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2026.119751_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12865-019-0309-9","article-title":"CD4(+) T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B","volume":"20","author":"Dong","year":"2019","journal-title":"BMC Immunol."},{"issue":"15","key":"10.1016\/j.biopha.2026.119751_bib46","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2026.119751_bib47","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/bloodadvances.2020003080","article-title":"Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade","volume":"5","author":"Roussel","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.biopha.2026.119751_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqad006","article-title":"The current state and future of T-cell exhaustion research","volume":"4","author":"Jenkins","year":"2023","journal-title":"Oxf. Open. Immunol."},{"issue":"37","key":"10.1016\/j.biopha.2026.119751_bib49","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2026.119751_bib50","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon gamma and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2026.119751_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.05.002","article-title":"IFN-gamma: A cytokine at the right time, is in the right place","volume":"43","author":"Burke","year":"2019","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119751_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12441","article-title":"Anti-cancer therapy with TNFalpha and IFNgamma: a comprehensive review","volume":"51","author":"Shen","year":"2018","journal-title":"Cell. Prolif."},{"issue":"5","key":"10.1016\/j.biopha.2026.119751_bib53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0952-7915(03)00107-9","article-title":"Granzyme B: pro-apoptotic, antiviral and antitumor functions","volume":"15","author":"Trapani","year":"2003","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119751_bib54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.anai.2022.10.025","article-title":"Interleukin-6 and cytokine release syndrome: A new understanding in drug hypersensitivity reactions","volume":"130","author":"Lee","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:42:48Z","timestamp":1787179368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"alternative-id":["S0753332226007870"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119751","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual bispecific protein engager\u2013armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119751"}}